AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34562209 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided oblique subcostal transversus abdominis plane block (TAPB)
Number of subjects: 60
Study 36469484 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical face mask (FM)
Number of subjects: 16
Study 36469484 — intervention group
Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 16
Study 34183702 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600-1800 mg
Number of subjects: 49
Study 34183702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 34183702 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 49
Study 32758267 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion reirradiation (reCIRT)
Number of subjects: 72
Study 32758267 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated re-radiotherapy (reIMRT)
Number of subjects: 72
Study 34503349 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily along with 9 cycles of CyBorD
Number of subjects: 140
Study 34503349 — intervention group
Group type: COMPARATOR
Intervention: CyBorD alone (control group)
Number of subjects: 140
Study 32782904 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Prevention Program (IPP); 30-minute exercise program, 3 times per week for 52 weeks
Number of subjects: 39
Study 32782904 — intervention group
Group type: COMPARATOR
Intervention: Control group; standard operating practice without changes
Number of subjects: 39
Study 32782904 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Prevention Program (IPP)
Number of subjects: 39
Study 35261932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (sitagliptin + spironolactone)
Number of subjects: 263
Study 35261932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin add-on
Number of subjects: 263
Study 35261932 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone add-on
Number of subjects: 263
Study 35261932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 263
Study 35261932 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 263
Study 35261932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 263
Study 35261932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 263
Study 32560745 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for COVID-19 + dexamethasone (administered within the first 24 hours)
Number of subjects: 105
Study 32560745 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for COVID-19 + dexamethasone (administered within the first 24 hours for 48-72 hours)
Number of subjects: 105
Study 32560745 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for COVID-19 (Control Group)
Number of subjects: 105
Study 33632377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (1000 mg ferric carboxymaltose)
Number of subjects: 487
Study 33632377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 487
Study 32430774 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-occlusion biofeedback (BFB) splint
Number of subjects: 41
Study 32430774 — intervention group
Group type: COMPARATOR
Intervention: Adjusted occlusal splint (AOS)
Number of subjects: 41
Study 34477963 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerated 2% lignocaine HCl with 1:100,000 epinephrine (LE) after topical ice application for 15 seconds
Number of subjects: 60
Study 34477963 — intervention group
Group type: COMPARATOR
Intervention: Conventional LE infiltration after topical gel application for 1 minute
Number of subjects: 60
Study 34151843 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing nutrition (IMN)
Number of subjects: 88
Study 34151843 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet and IMN
Number of subjects: 88
Study 34151843 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 88
Study 32516227 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Me [S(+)‐ketamine and methadone]
Number of subjects: 96
Study 32516227 — intervention group
Group type: COMPARATOR
Intervention: 0-Mo (placebo and morphine)
Number of subjects: 96
Study 32516227 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-Me (placebo and methadone)
Number of subjects: 96
Study 36178335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily (q.d.)
Number of subjects: 256
Study 36178335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 40 mg once daily (q.d.)
Number of subjects: 256
Study 36178335 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily (q.d.)
Number of subjects: 256
Study 33785490 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab (900 mg intravenous dose)
Number of subjects: 51
Study 33785490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 33172128 — intervention group
Group type: EXPERIMENTAL
Intervention: Label with a claim present
Number of subjects: 1997
Study 33172128 — intervention group
Group type: COMPARATOR
Intervention: Label with a claim absent
Number of subjects: 1997
Study 33172128 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol depicting ‘health’ present
Number of subjects: 1997
Study 33172128 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants using NFt
Number of subjects: 1997
Study 33172128 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants making decisions implicitly
Number of subjects: 1997
Study 36066725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy
Number of subjects: 780
Study 36066725 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 780
Study 33153401 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 100
Study 33153401 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular weight heparin (enoxaparin)
Number of subjects: 100
Study 32951337 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based planning (KBP)
Number of subjects: 60
Study 32951337 — intervention group
Group type: COMPARATOR
Intervention: Clinical plan (CL)
Number of subjects: 60
Study 35437957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQs) for 1 month
Number of subjects: 60
Study 35437957 — intervention group
Group type: COMPARATOR
Intervention: Combination of FQs with cephalosporins/macrolides for 1 month
Number of subjects: 60
Study 33780544 — intervention group
Group type: EXPERIMENTAL
Intervention: HO-ASE
Number of subjects: 282441
Study 33780544 — intervention group
Group type: COMPARATOR
Intervention: Reportable HAIs
Number of subjects: 282441
Study 33780544 — intervention group
Group type: EXPERIMENTAL
Intervention: HO-ASE missed by reportable HAIs
Number of subjects: 282441
Study 33780544 — intervention group
Group type: COMPARATOR
Intervention: Reportable HAIs missed by HO-ASE
Number of subjects: 282441
Study 33780544 — intervention group
Group type: EXPERIMENTAL
Intervention: HO-ASEs
Number of subjects: 282441
Study 32826158 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg and 30 mg doses)
Number of subjects: 2680
Study 32826158 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin lead-in
Number of subjects: 2680
Study 35353979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (400 µg per kilogram of body weight) once daily for 3 days
Number of subjects: 3515
Study 35353979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3515
Study 35353979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (modified intention-to-treat analysis)
Number of subjects: 3515
Study 35353979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (per-protocol analysis)
Number of subjects: 3515
Study 35311524 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-1633 (0.033, 0.165, or 0.330 mg/kg)
Number of subjects: 24
Study 35311524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study 35311524 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-1633 (0.330 mg/kg)
Number of subjects: 24
Study 32144522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 32144522 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg kg-1 IV‐TXA and 20 mg IV‐DXM
Number of subjects: 125
Study 32144522 — intervention group
Group type: EXPERIMENTAL
Intervention: Six doses of IV‐TXA (total dosage > 6 g)
Number of subjects: 125
Study 32144522 — intervention group
Group type: EXPERIMENTAL
Intervention: Six doses of IV‐TXA combined with three doses of IV‐DXM (total dosage = 40 mg)
Number of subjects: 125
Study 35970494 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined myo-inositol, probiotics, and micronutrient supplementation
Number of subjects: 589
Study 35970494 — intervention group
Group type: COMPARATOR
Intervention: Standard micronutrient supplement (control)
Number of subjects: 589
Study 33348420 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib prior to carboplatin, etoposide and atezolizumab (E/P/A)
Number of subjects: 105
Study 33348420 — intervention group
Group type: COMPARATOR
Intervention: Placebo prior to carboplatin, etoposide and atezolizumab (E/P/A)
Number of subjects: 105
Study 34225321 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise, 3-4 days/week, 25-40 min, 14 ± 1 wk
Number of subjects: 59
Study 34225321 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control), n = 28
Number of subjects: 59
Study 34448003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 34448003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 36018541 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cryoneurolysis
Number of subjects: 16
Study 36018541 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 16
Study 33333410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) 2 mg continuously
Number of subjects: 150
Study 33333410 — intervention group
Group type: COMPARATOR
Intervention: Dydrogesterone (DYG)
Number of subjects: 150
Study 34533189 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - 4 points of BTX‐A application (2 U/point) for relaxation of the levator labii superioris alaeque nasi and levator labii superioris muscles
Number of subjects: 0
Study 34533189 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - 2 points of BTX‐A (2 U/point) for relaxation of only the levator labii superioris alaeque nasi muscle
Number of subjects: 0
Study 32209570 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel regimen + nintedanib
Number of subjects: 188
Study 32209570 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete interval debulking surgery (IDS)
Number of subjects: 188
Study 34844929 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and education programme
Number of subjects: 206
Study 34844929 — intervention group
Group type: COMPARATOR
Intervention: Intra‐articular saline injections
Number of subjects: 206
Study 36066863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror exposure (four sessions)
Number of subjects: 0
Study 36066863 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (4 weeks waiting period)
Number of subjects: 0
Study 34190419 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC formulation of bazedoxifene 20 mg and cholecalciferol 8 mg
Number of subjects: 52
Study 34190419 — intervention group
Group type: COMPARATOR
Intervention: Individual component tablets of bazedoxifene and cholecalciferol
Number of subjects: 52
Study 35404638 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral reconation therapy (MRT)
Number of subjects: 341
Study 35404638 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 341
Study 35404638 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral reconation therapy (MRT) (per-protocol analysis)
Number of subjects: 341
Study 35404638 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) (per-protocol analysis)
Number of subjects: 341
Study 33753353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study 33753353 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation
Number of subjects: 0
Study 33753353 — intervention group
Group type: EXPERIMENTAL
Intervention: Heritability estimates
Number of subjects: 0
Study 32503599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg
Number of subjects: 7012
Study 32503599 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 7012
Study 32503599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Number of subjects: 7012
Study 32503599 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 7012
Study 32503599 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 7012
Study 32503599 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 7012
Study 35936982 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine nursing and DEX‐assisted anesthesia (Group A)
Number of subjects: 66
Study 35936982 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfortable nursing and DEX‐assisted anesthesia (Group B)
Number of subjects: 66
Study 35936982 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine nursing and anesthesia)
Number of subjects: 66
Study 33740099 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-R132H IDH1/2 mutations
Number of subjects: 0
Study 33740099 — intervention group
Group type: COMPARATOR
Intervention: IDH1-R132H mutations
Number of subjects: 0
Study 32580918 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV) administered in 0, 1, 2, and 3 dose schedules at 6, 10, and 14 weeks of age
Number of subjects: 364
Study 33952669 — intervention group
Group type: EXPERIMENTAL
Intervention: GMEX rapid point-of-care CYP2C19 genotyping system
Number of subjects: 408
Study 33952669 — intervention group
Group type: COMPARATOR
Intervention: YZY Kit (laboratory-based technology)
Number of subjects: 408
Study 35595376 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogates of patients with SABI
Number of subjects: 206
Study 35595376 — intervention group
Group type: COMPARATOR
Intervention: Surrogates of non-SABI patients
Number of subjects: 206
Study 32591238 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 58
Study 32591238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 34048978 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically modified hybrid aspens
Number of subjects: 0
Study 34048978 — intervention group
Group type: COMPARATOR
Intervention: Natural accessions of P. tremula
Number of subjects: 0
Study 35780325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU of vitamin D3 monthly for 5 years)
Number of subjects: 21315
Study 34225200 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress + ADP group (HSA, basal diet supplemented with 1,000 mg/kg ADP)
Number of subjects: 144
Study 34225200 — intervention group
Group type: COMPARATOR
Intervention: Heat stress group (HS, fed basal diet)
Number of subjects: 144
Study 34225200 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress + ADP group (HSA)
Number of subjects: 144
Study 34225200 — intervention group
Group type: COMPARATOR
Intervention: Heat stress group (HS)
Number of subjects: 144
Study 33080407 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic lung ultrasound at various PEEP levels (4 to 20 cmH2O)
Number of subjects: 18
Study 33080407 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic lung ultrasound
Number of subjects: 18
Study 35476296 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil observation
Number of subjects: 12
Study 35476296 — intervention group
Group type: COMPARATOR
Intervention: The Observer XT® desktop software
Number of subjects: 12
Study 35476296 — intervention group
Group type: COMPARATOR
Intervention: Big Eye Observer® smartphone application
Number of subjects: 12
Study 32197853 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal colostrum (MC)
Number of subjects: 60
Study 32197853 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial whey-based colostrum replacer (CR) 150 g of IgG
Number of subjects: 60
Study 32197853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-quality maternal colostrum (LMC) supplemented with CR (LMC-CR)
Number of subjects: 60
Study 32197853 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial whey-based colostrum replacer (CR) 110 g of IgG
Number of subjects: 60
Study 35549802 — intervention group
Group type: COMPARATOR
Intervention: Thrombopoietin mimetic peptide 0.3 μg/kg
Number of subjects: 30
Study 35549802 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin mimetic peptide 1.0 μg/kg
Number of subjects: 30
Study 35549802 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin mimetic peptide 2.0 μg/kg
Number of subjects: 30
Study 35549802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33831502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodic tDCS with balance training
Number of subjects: 82
Study 33831502 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with balance training
Number of subjects: 82
Study 33438234 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of EF to >35% at first follow-up
Number of subjects: 1178
Study 33438234 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of EF to ≤35% at second follow-up
Number of subjects: 1178
Study 33438234 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of EF by >10% at first follow-up
Number of subjects: 1178
Study 33438234 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of EF by >10% at second follow-up
Number of subjects: 1178
Study 33438234 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of EF (≥55%) at first follow-up
Number of subjects: 1178
Study 33438234 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of improvement in EF between ischemic and nonischemic cardiomyopathy
Number of subjects: 1178
Study 32259214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Number of subjects: 0
Study 32259214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33978196 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine-containing disinfectant and multi-enzyme detergent
Number of subjects: 6
Study 33978196 — intervention group
Group type: COMPARATOR
Intervention: Chlorine-containing disinfectant
Number of subjects: 6
Study 36123934 — intervention group
Group type: EXPERIMENTAL
Intervention: ISU303 (Agalsidase beta), 1 mg/kg dose administered every other week for 6 months
Number of subjects: 10
Study 34107551 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-dual therapy
Number of subjects: 59
Study 34107551 — intervention group
Group type: COMPARATOR
Intervention: VAC-triple therapy
Number of subjects: 59
Study 36232037 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher incentives (high-value sunglasses worth USD 148, moderate-value eyeglasses worth USD 89, cash incentives USD 35)
Number of subjects: 3401
Study 36232037 — intervention group
Group type: COMPARATOR
Intervention: No teacher incentives offered (control group)
Number of subjects: 3401
Study 34706171 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab (300 mg)
Number of subjects: 296
Study 34706171 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab plus dupilumab (both at 300 mg)
Number of subjects: 296
Study 34706171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg)
Number of subjects: 296
Study 34706171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 34706171 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab
Number of subjects: 296
Study 34706171 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab and Dupilumab monotherapies
Number of subjects: 296
Study 34706171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Itepekimab plus Dupilumab)
Number of subjects: 296
Study 34706171 — intervention group
Group type: EXPERIMENTAL
Intervention: All trial groups
Number of subjects: 296
Study 36006665 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based life review program
Number of subjects: 150
Study 36006665 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (friendly visiting)
Number of subjects: 150
Study 36006665 — intervention group
Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 150
Study 34684511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 67
Study 34684511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 67
Study 34684511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status above 75 nmol/L
Number of subjects: 67
Study 32434638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.3 mg/kg)
Number of subjects: 70
Study 32434638 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular phenobarbital sodium (10 mg/kg)
Number of subjects: 70
Study 32434638 — intervention group
Group type: COMPARATOR
Intervention: Control group (phenobarbital sodium)
Number of subjects: 70
Study 35610711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation training and social recovery focused cognitive behavioural therapy
Number of subjects: 0
Study 35610711 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32591862 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL
Number of subjects: 41
Study 32591862 — intervention group
Group type: COMPARATOR
Intervention: Control (standard follow-up)
Number of subjects: 41
Study 34859460 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 16
Study 34859460 — intervention group
Group type: COMPARATOR
Intervention: Intralesional corticosteroids (ILCS)
Number of subjects: 16